Ignite Creation Date:
2025-12-24 @ 9:48 PM
Ignite Modification Date:
2025-12-31 @ 12:05 PM
Study NCT ID:
NCT04597632
Status:
COMPLETED
Last Update Posted:
2024-10-09
First Post:
2020-10-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-12-16
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-28
Completion Date Type:
ACTUAL
First Submit Date:
2020-10-01
First Submit QC Date:
None
Study First Post Date:
2020-10-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-02-27
Results First Submit QC Date:
None
Results First Post Date:
2024-04-04
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-07
Last Update Post Date:
2024-10-09
Last Update Post Date Type:
ACTUAL